CASE REPORT

A novel RUNX1 exon 3 - 7 deletion causing a familial platelet disorder

Ibrahim Almazni1, Pavel Chudakov2, Alison Dawson-Meadows2, Kate Downes3, Kathleen Feson4, Joanne Mason5, Paula Page5, Kim Reay5, Bethan Myers2,6, & Neil V Morgan on behalf of the UK GAPP Study Group

1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK, 2Department of Haematology, Lincoln County Hospital, Lincoln, UK, 3East Genomic Laboratory Hub, Cambridge University Hospitals, Cambridge, UK, 4Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium, 5West Midlands Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK, and 6Department of Haematology, University Hospitals of Leicester, Leicester, UK

Abstract

Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) is a rare inherited disorder confirmed with the presence of a pathogenic germline RUNX1 variant and is thought to be heavily underdiagnosed. RUNX1 has also been found to be mutated in up to 10% of adult AML cases and other cell malignancies. We performed targeted next-generation sequencing and subsequent MLPA analysis in a kindred with multiple affected individuals with low platelet counts and a bleeding history. We detected a novel heterozygous exon 3–7 large deletion in the RUNX1 gene in all affected family members which is predicted to remove all of the Runt-homology DNA-binding domain and a portion of the Activation domain. Our results show that the combination of targeted NGS and MLPA analysis is an effective way to detect copy number variants (CNVs) which would be missed by conventional sequencing methods. This precise diagnosis offers the possibility of accurate counselling and clinical management in such patients who could go onto develop other cell malignancies.

Introduction

Inherited thrombocytopenias (ITs) comprise a heterogeneous group of disorders with a sustained reduction in platelet count which often manifest as a bleeding diathesis. To date, 26 forms of IT have been reported with known disease associations in 30 genes which makes genetic diagnosis challenging [1–3]. A precise genetic diagnosis provides clinical benefits for the patients where some patients with IT have unnecessary procedures and treatments such as splenectomies or mistaken for idiopathic thrombocytopenic purpura (ITP), which may be treated with steroids or immunosuppressive drugs with many side effects. Some of the gene variants in IT patients, e.g., RUNX1 result in patients having a predisposition to hematological malignancies and once a genetic defect is proven the information can be used to monitor the patients’ hematological parameters more closely. Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) (OMIM# 601399) is confirmed with the presence of a pathogenic germline mutation in RUNX1. RUNX1 variants have been reported in approximately 10% of adult AML, which are mainly acquired but can also be germline and thought to be underdiagnosed [4]. This highlights the need for a definitive genetic diagnosis to aid clinical management of the condition.

Current Next-Generation Sequencing (NGS) technologies allow the detection of both point mutations and CNVs with a single platform and workflow [5–7]. In this study, we describe and elucidate the genetic basis of a single family with three affected individuals who suffer from a bleeding diathesis and low platelet counts with previously unknown genetic diagnosis.

Cases

The family presented here has three affected individuals, all with a strong family history of clinical bleeding including epistaxis and easy bruising associated with low platelet counts and recruited to the UK Genotyping and Phenotyping of Platelets (GAPP) study [8] (Figure 1A). The index case (P1) was a 67 year old male when initially recruited to the GAPP study with a 10 year history of a ‘probable’ hereditary platelet disorder. He had a history of bleeding episodes which included epistaxis, cutaneous bleeding, bleeding from minor wounds, GI bleeding, oral cavity bleeding, bleeding after tooth extraction and muscle hematomas. He bled excessively after a hip replacement. He had a platelet count of 129 x 10⁹/L and mean platelet volume (MPV) of 10.2 fl. He had Coronary artery bypass graft surgery aged 69 following which he suffered a thromboembolic stroke.

His relatives P2 and P3 (son and grandson, respectively) were also referred for genetic testing to the GAPP study. P2 is a 44 year old man with a clinical history of life-long mucosal-cutaneous bleeding. He had a platelet count of 83 x 10⁹/L and MPV of 9.3 fl. P3 is 22 years old with clinical features of platelet dysfunction. His platelet count at testing was 96 x 10⁹/L and MPV of 12.6 fl. (Table 1). To date, no evidence of AML or other associated hematological malignancies have been reported in any of these patients. All other hematological parameters were within normal ranges.

The index case P1 was subjected to the ThromboGenomics targeted sequencing platform (TGv3.0) [5] where CNVs are called using an experimental pipeline based on ExomeDepth [9] version 1.1.10. This detected a novel heterozygous CNV Deletion of RUNX1 from exons 3–7 (Figure 1B). The genetic variant was scored

Correspondence: Neil V Morgan, Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, Edgbaston, University of Birmingham, Birmingham B15 2TT, UK. Email: N.V.Morgan@bham.ac.uk.
Figure 1. Identification of a novel germline mutation in RUNX1 in a family with inherited thrombocytopenia (A) Pedigree of family showing affected individuals (shaded) and platelet counts (B) CNV analysis of sequencing data of P1 using ExomeDepth within the ThromboGenomics targeted sequencing platform, detected a novel heterozygous CNV deletion of RUNX1 spanning from exons 3–7. (C) MLPA analysis detects the heterozygous exon 3–7 deletion in RUNX1 in all patients (representative data shown from P1 only). MLPA peak ratios for kit P437-B1 including RUNX1 (red and green) and control (blue) MLPA test probes (left-hand panel). Table shows RUNX1 exon number or intron (int), bin size and peak ratios. Red, probes with peak ratios <0.75 indicate a heterozygous deletion (gray shaded) (right-hand panel). (D) Schematic showing the location of the novel exon 3–7 exons deleted within RUNX1 which are implicated in the FPD/AML family studied. The Runt-homology DNA-binding domain (RHD) spanning amino acids 77 to 204 and the Activation domain (TAD) spanning from amino acid 269 to 438 is also displayed. Alterations are numbered according to positions in the NM_001754.4 transcript for RUNX1 (RUNX1c isoform). Positions of different types of published RUNX1 variants causing FPDMM are also shown where RUNX1 missense variants are almost exclusively located in the Runt homology DNA-binding domain. Reported gross deletions are shown with solid lines and a gross duplication with dashed line.

Table I. Results of hematological analysis in patients P1-P3 at time of recruitment.

| Laboratory analysis        | P1          | P2          | P3          | Normal range |
|----------------------------|-------------|-------------|-------------|--------------|
| Hemoglobin                 | 14.0 g/dL   | 14.3        | 14.2        | 13.5–17.5    |
| MCV                        | 91.8 fl     | 90.6        | 93.8        | 80.0–94.0    |
| Hematocrit                 | 40.5%       | 40.5        | 40.7        | 41.0–53      |
| Red cell count             | 4.41 × 10¹²/L | 4.47        | 4.34        | 3.8–6.5      |
| White cell count           | 5.37 × 10⁹/L | 6.26        | 5.08        | 4.8–10.8     |
| Neutrophils                | 3.71 × 10⁹ /L / (69.1%) | 3.38 × 10⁹ /L / (54.0%) | 2.27 × 10⁹ /L (44.7%) /L | 1.5–6.5     |
| Lymphocytes                | 0.77 × 10⁹ /L (14.3%) /L | 1.68 × 10⁹ /L (26.8%) /L | 1.39 × 10⁹ /L (27.4%) /L | 1.2–3.4     |
| Monocytes                  | 0.68 × 10⁹ /L (12.7%) /L | 0.67 × 10⁹ /L (10.7%) /L | 0.91 × 10⁹ (17.9%) /L | 0.2–0.8     |
| Eosinophils                | 0.20 × 10⁹ (3.7%) /L | 0.52 × 10⁹ (8.3%) /L | 0.49 × 10⁹ (9.6%) /L | 0–0.4       |
| Basophils                  | 0.01 × 10⁹ /L (0.2%) /L | 0.01 × 10⁹ /L (0.2%) /L | 0.02 × 10⁹ (0.4%) /L | 0–0.1       |
| Platelets                  | 129 × 10⁹ /L | 83 × 10⁹ /L | 96 × 10⁹ /L | 147–327     |
| Mean platelet volume       | 10.2 fl     | 9.3         | 12.6        | 7.8–12.69    |
| Immature platelet fraction | 5.4%        | 2.3         | 13.6        | 1.3–10.8     |
| Reticulocytes              | 67.0 × 10⁹ /L (1.52%) | 91.6 × 10⁹ /L (2.05%) | 81.6 × 10⁹ /L (1.88%) | 20–80 (0.2–2%) |
with strong evidence of pathogenicity based on the current ACMG guidelines [10] (PM2-Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium, PV1 - Null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, single or multiexon deletion) in a gene where LOF is a known mechanism of disease). To confirm if the RUNX1 CNV deletion was present in all affected patients, Multiplex ligation-dependent probe amplification (MLPA) analysis was performed which includes all exons of the RUNX1/CEBPA/GATA2/TERC/TERT genes (MRC Holland kit P437-B1), and can detect both deletions and duplications. The index patient P1 and relatives P2 and P3 were all confirmed to have the heterozygous RUNX1 exon 3–7 deletion by MLPA analysis (Figure 1C). The deletion removes 870 bp of the mRNA sequence of RUNX1 which is in frame, but completely removes the DNA/Runt DNA-binding domain and part of the activation domain (Figure 1D).

Discussion

This report describes a family with an inherited thrombocytopenia and history of excessive bleeding. FPDM is confirmed in this family studied with the presence of a pathogenic germ-line RUNX1 mutation [11–13]. To date, more than 70 FPDM families have been reported with a 40% lifetime risk of developing MDS and/or AML [14]. While the majority of familial cases reported in the literature with RUNX1 mutations are point mutations, different extended deletions have also been described [5,11,15,16] (Figure 1D). Here using targeted NGS and subsequent CNV/MLPA analysis, we have detected a novel heterozygous deletion covering exons 3–7 of the RUNX1 gene which is predicted to remove the entire DNA Runt/DNA binding domain. RUNX1/AML1 encodes the DNA-binding unit of the heterodimeric core-binding factor (CBF) that is a critical regulator of definitive hematopoiesis [17]. RUNX1 is also a recurrently mutated gene in sporadic myelodysplastic syndrome and leukemia. In sporadic AML, mutations in RUNX1 are usually secondary events, whereas in FPDM they are initiating events. None of the patients included in this study have developed AML as a result of a secondary somatic event occurring within RUNX1 to date. It is thought that RUNX1 variants causing haploinsufficiency are thought to be associated with a lower incidence of myeloid malignancies when compared to those patients with dominant negative RUNX1 defects. The detection of a RUNX1 variant in such patients with low platelet counts allows the possibility of accurate counseling and clinical management for both them and extended family members at 50% risk of inheriting the pathogenic variant, whom could go onto develop other cell malignancies.

Acknowledgements

The authors would like to thank the family and patients for taking part in the study. The work in the author’s laboratories is supported by the British Heart Foundation (PG/13/36/30275; FS/15/18/31317; PG/16/103/32650; FS/18/11/33443; NVM) and the Saudi Arabia Cultural Bureau in London (IA).

Disclosure of conflicts of interest

The authors report no conflicts of interest

Supplementary acknowledgements

The members of the UK Genotyping and Phenotyping of Platelets Study Group are; Neil Morgan, Steve Watson, Gillian Lowe, Paul Harrison, Marie Lordkipanidze (University of Birmingham); Andrew D Mumford and Stuart J Mundell (University of Bristol); Paul Gissen (University College London); Martina E. Daly (University of Sheffield); Will Lester and Justin Clark (Birmingham Women’s Hospital); Mike Williams, Jayashree Motwani, Dianne Marshall, Natalie Lawson, Priscilla Nyatanga, Pat Mann, and Julie Kirwan (Birmingham Children’s Hospital); Will Lester, Charles Percy, Pam Green, Helen Huspton, Koonmaral Nagapacketty, Elizabeth Dwenger, Ann O Rourke, Martin Pope, Camilla Edmead and April Greenway (University Hospital Birmingham); Michael Makris (Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital); Jeanette Payne (Paediatric Haematology Centre, Sheffield Children’s Hospital); Sue Pavord, Richard Gooding and Rashesh Dattani (University Hospitals Leicester); Gerry Dolan Charlotte Grimey, Simone Stokley, Emma Astwood, Karyn Longmuir, Cherry Chang, Merri Foros, Michelle Kightley and Linda Trower (Nottingham University Hospitals); Jeckie Thachil (previously Paula Bolton Maggs), Charlie Hay, Gill Pike, Andrew Will, John Grainger, Matt Foukes, and Mona Fareh (Central Manchester National Health Service Foundation Trust); Kate Talks, Tina Biss, Patrick Kesteven, John Hanley, Julie Vowles, Lesley Basey, Kevin Knaggs and Michelle Barnes (Newcastle upon Tyne Hospitals NHS Trust); Peter Collins, Rachel Rayment, Raza Alkhan, Ana Guerrero Rebecca Morris, and Dianne Mansell (Cardiff and Vale University Local Health Board); Cheng Hock Toh and Vanessa Martlew (Royal Liverpool University Hospitals); Elaine Murphy and Robin Lachmann (University College London Hospitals NHS Trust); Peter Rose, Oliver Chapman, Anand Lokare, Kathryn Marshall, and Naseem Khan (University Hospitals Coventry and Warwickshire); David Keeling, Nikki Curry and Paul Giangrande (Oxford Radcliffe Hospitals NHS Trust); Steve Austin, David Bevan and Jayanthi Alamelu (Gyps’ and St. Thomas’ NHS Foundation Trust); David Allsup, Andrew Fletcher, Katherine Gladstone, Jeanette Fenwick, Philippa Woods and Darren Camp (Hull and East Yorkshire Hospitals NHS trust, Castle Hill Hospital, Hull); Beki James, Suzie Preston, Collette Spencer, Alexandra Pike and Chung Lai-Wah (Leeds Teaching Hospitals NHS trust); Angela Thomas (Royal Hospital for Sick Children Edinburgh); Bethan Myers (Lincoln County Hospital); Gillian Evans, Kim Elliot, Karen Davies, Charlotte Graham and Miranda Foad, (Kent and Canterbury Hospital); Jacqueline Smith (The Dudley Group NHS Foundation Trust).

Dr Neil Morgan has authorized authorship on behalf of the UK Genotyping and Phenotyping of Platelets Study Group.

ORCID

Neil V Morgan http://orcid.org/0000-0001-6433-5692

Funding

This work was supported by the British Heart Foundation [FS/15/18/31317, FS/18/11/33443, PG/13/36/30275, PG/16/103/32650]; Saudi Arabia Cultural Bureau in London.

References

1. Almazni I, Stapley R, Morgan NV. Inherited thrombocytopenia: update on genes and genetic variants which may be associated with bleeding. Front Cardiovasc Med 2019;6:80. doi:10.3389/fcmv.2019.00080.
2. Johnson B, Doak R, Allsup D, Astwood E, Evans G, Grimey C, James B, Myers B, Stokley S, Thachil J et al. A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia. Res Pract Thromb Haemost 2018;2:640–652. doi:10.1002/rth.2.12151.
3. Johnson B, Fletcher SJ, Morgan NV. Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan. Platelets 2016;27:519–525. doi:10.3109/09537304.2016.1148806.
4. Simon L, Spinella JF, Yao CY, Lavallée V-P, Boivin I, Boucher G, Audemard E, Bordeaux M-E, Lemieux S, Hébert J, et al. High

Authorship contribution

NVM designed the study; BM recruited the patients; IA, PC, AD-M, KD, KF, BM, and NVM extracted or generated clinical or experimental data; IA, KD, KF, JM, PP, KR, and NVM interpreted the results; KD, and NVM undertook governance of the study; BM and NVM wrote the manuscript; all authors read and approved the final version of the manuscript.
